Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 3, 1999, Pages 206-211

  Kai, Tatsuya ^a   Sugimura, Keiichi ^a   Shimada, Seijiro ^a   Kurooka, Atsuhiro ^a   Ishikawa, Kinji ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arteritis; Blood pressure; Cardiac hypertrophy; Glomerulosclerosis; Renin angiotensin system; Survival rate; Transgenic mice

Indexed keywords

ALBUMIN; HYDRALAZINE; LISINOPRIL; PENTOBARBITAL;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FLUID INTAKE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; HYPERTENSION; KIDNEY DISEASE; MOUSE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; URINE VOLUME;

ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; HUMANS; HYDRALAZINE; HYPERTENSION; KIDNEY DISEASES; LISINOPRIL; MICE; MICE, INBRED C57BL; RENIN; RENIN-ANGIOTENSIN SYSTEM; SURVIVAL RATE;

EID: 0032986667     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03023.x     Document Type: Article

References (47)

1. 1. Frolich ED. The heart in hypertension: A 1991 overview. Hypertension 1991; 18 (Suppl. 3): 62-8.
2. 2. Hollenberg NK. Pharmacologic interruption of the renin-angiotensin system. Annu. Rev. Pharmacol. Toxicol. 1979; 19: 559-82.
3. 3. Peach MJ. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol. Rev. 1977; 57: 313-70.
4. 4. Kostis JB. Angiotensin converting enzyme inhibitors. II. Clinical use. Am. Heart J. 1988; 116: 1591-605.
5. 5. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995; 92: 3105-12.
6. 6. Dzau VJ, Re RN. Evidence for the existence of renin in the heart. Circulation 1987; 75 (suppl. 1): 134-6.
7. 7. Linz W, Schölkens BA, Lindpaintner K, Ganten D. Cardiac renin-angiotensin system. Am. J. Hypertens. 1989; 2: 307-10.
8. 8. Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong WF. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal, and pituitary of the rat. Proc. Natl Acad. Sci. USA 1986; 83: 7552-6.
9. 9. Dzau VJ. Short-and long-term determinants of cardiovascular function and therapy: Contributions of circulating and tissue renin-angiotensin systems. J. Cardiovasc. Pharmacol. 1989; 14 (suppl. 4): S1-5.
10. 10. Lees KR, MacFadyen RJ, Reid JL. Tissue angiotensin converting enzyme inhibition. Relevant to clinical practice? Am. J. Hypertens. 1990; 3: S266-72.
11. 11. Veltmar A, Gohlke P, Unger T. From tissue angiotensin converting enzyme inhibition to antihypertensive effect. Am. J. Hypertens. 1991; 4: S263-9.
12. 12. Fukamizu A, Sugimura K, Takimoto E et al. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and angiotensinogen genes. J. Biol. Chem. 1993; 268: 11617-21.
13. 13. Kai T, Shimada S, Kurooka A, Takenaka T, Ishikawa K. Tissue angiotensin II concentration in the heart and kidneys in transgenic Tsukuba hypertensive mice. Blood Pressure 1998; 7: 61-3.
14. 14. Kai T, Sugimura K, Shimada S, Kurooka A, Takenaka T, Ishikawa K. Enhanced angiotensin II stimulates renal disorders in transgenic Tsukuba hypertensive mice. Blood Pressure 1998; 7: 247-50.
15. 15. Kai T, Kino H, Ishikawa K. Role of the renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in transgenic hypertensive mice carrying both human renin and angiotensinogen genes. Hypertens. Res. 1998; 21: 39-46.
16. 16. Kai T, Shimada S, Sugimura K et al. Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. J. Hypertens. 1998 (in press).
17. 17. Kuwahara M, Sugano S, Yayou K, Tsubone H, Kobayashi H. Evalution of a new tail-cuff method for blood pressure measurement in rats with special reference to the effects of ambient tenperature. Exp. Anim. 1991; 40: 331-6.
18. 18. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T. Angiotensin blockade and progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993; 21: 975-9.
19. 19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457-81.
20. 20. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens. 1992; 6: 85-90.
21. 21. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. Am. J. Hypertens. 1992; 5: 95-110.
22. 22. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch. Intern. Med. 1995; 155: 1073-80.
23. 23. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann. Intern. Med. 1997; 127: 337-45.
24. 24. Neaton JD, Grimm Jr RH, Prineas RJ et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713-24.
25. 25. Johnson RJ, Alpers CE, Yoshimura A et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-74.
26. 26. Böhm M, Lee M, Kreutz R et al. Angiotensin II receptor blockade in TGR (mREN2), 27: Effects of renin-angiotensin system gene expression and cardiovascular functions. J. Hypertens. 1995; 13: 891-9.
27. 27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993, 329: 1456-62.
28. 28. Kai T, Kino H, Sugimura K et al. Significant role of the increase in renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in double transgenic Tsukuba hypertensive mice carrying both human renin and angiotensinogen genes. Clin. Exp. Hypertens. 1998; 20: 439-49.
29. 29. Kai T, Sugimura K, Shimada S, Kurooka A, Takenaka T, Ishikawa K. Inhibitory effects of a subdepressor dose of L-158 809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. Jpn. Circ. J. 1998; 62: 599-603.
30. 30. Rojo-Ortega JM, Yeghiayan E, Genest J. The thymus of spontaneously hypertensive rats. Light and electron microscopic studies. Clin. Sci. Mol. Med. 1973; 45: S141-4.
31. 31. Khraibi AA. Association between disturbances in the immune system and hypertension. Am. J. Hypertens. 1991; 4: 635-41.
32. 32. Ishimitsu T, Uehara Y, Mumabe A et al. Interferon gamma attenuates hypertensive renal injury in salt-sensitive Dahl rats. Hypertension 1992; 19: 804-8.
33. 33. Rapp JP, Wang SM, Dene H. A genetic polymorphism in the renin gene of Dahl rat co-segregates with blood pressure. Science 1989; 243: 542-4.
34. 34. Kurtz TW, Simonet L, Kabra PM, Wolfe S, Chan L, Hjelle BL. Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J. Clin. Invest. 1990; 85: 1328-32.
35. 35. Goldby FS, Beilin LJ. How an acute rise in arterial pressure damages arterioles: Electron microscopic changes during angiotensin infusion. Cardiovasc. Res. 1972; 6: 569-84.
36. 36. Kahn JR, Skeggs LT, Shumway NP, Wisenbaugh PE. The assay of hypertension from the blood of normotensive and hypertensive human beings. J. Exp. Med. 1952; 95: 523-9.
37. 37. Massani ZM, Finkielman S, Worcel M, Agrest A, Paladini AC. Angiotensin blood levels in hypertensive and non-hypertensive disease. Clin. Sci. 1966; 30: 473-83.
38. 38. Goldblatt H. Studies in experimental hypertension: Production of malignant phase of hypertension. J. Exp. Med. 1938; 67: 809-26.
39. 39. Kincaid-Smith P. Malignant hypertension. J. Hypertens. 1991; 9: 893-9.
40. 40. Ohta G, Cohen S, Singer EJ, Strauss L. Demonstration of gamma globulin in vascular lesions of experimental necrotizing arteritis in the rat. Proc. Soc. Exp. Biol. Med. 1959; 102: 187-9.
41. 41. White FN, Grollman A. Experimental periarteritis nodusa in the rat. Arch. Pathol. 1964; 78: 31-6.
42. 42. Olsen F. Evidence for an immunological factor in the hypertensive vascular disease. Acta Pathol. Scand. 1971; 79: A22-6.
43. 43. Keane WF, Anderson S, Aurell M, Zeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Ann. Intern. Med. 1989; 111: 503-16.
44. 44. Anderson S, Rennke KG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
45. 45. Fyhrquist F. Clinical pharmacology of the ACE inhibitors. Drugs 1986; 32 (Suppl. 5): 33-9.
46. 46. Velasco M, McNay JL. Physiologic mechanisms of bupicomide-and hydralazine-induced increase in plasma renin activity in hypertensive patients. Mayo Clin. Proc. 1977; 52: 430-2.
47. 47. Reeves RA, Smith DL, Leenen FHH. Hemodynamic interaction of non-selective vs beta-1-selective beta-blockade with hydralazine in normal humans. Clin. Pharmacol. Ther. 1987; 41: 326-35.